ArticleInfectious agents and cancer2026
Primary hepatic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma: a rare case with genomic profiling and therapeutic implications.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma (EBV+IFDCS) is an extremely rare low-grade malignant tumor. Due to its rarity and lack of specific symptoms, laboratory markers, or characteristic imaging features, this disease is frequently misdiagnosed. A 50-year-old woman was diagnosed with left hepatic mass and underwent laparoscopic left hemihepatectomy. The postoperative histopathology confirmed EBV+IFDCS. To our knowledge, we conducted the first-ever genetic testing for hepatic EBV+IFDCS. The analysis indicates that the patient has a low tumor mutational burden and low microsatellite instability, with no identifiable targetable gene mutations, but may have potential sensitivity to certain chemotherapy agents. Postoperatively, the patient was empirically treated with six cycles of S-1 chemotherapy (60 mg twice daily, 2 weeks on/1 week off), and the recovery process was uneventful. We hope that our findings may contribute to the understanding and clinical management of this disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.